EI
NAVB

EAM Investors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

EAM Investors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-40,613
Closed -$1.85M – 384
2015
Q3 		$1.85M Buy
+40,613
New +$1.53M 0.29% 157

Other funds holding NAVB

CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Investors's NAVB Position: Q4 2015 in Review

EAM Investors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2015, closing a stake of 40,613 shares — an estimated $1.85M sold.

EAM Investors first reported a position in NAVB in Q3 2015 and held it in 1 quarter. The position peaked at $1.85M in Q3 2015. 78 funds tracked by Wall St. Rank hold NAVB as of Q4 2015.

  • EAM Investors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
  • EAM Investors sold 40,613 Navidea Biopharmaceuticals Inc. shares in Q4 2015, an estimated $1.85M.
  • EAM Investors first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2015 and held it in 1 quarter.
  • EAM Investors's Navidea Biopharmaceuticals Inc. position peaked at $1.85M in Q3 2015.
  • 78 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2015.

Based on EAM Investors's 13F filing for Q4 2015, filed 5 Feb 2016.